Document Detail


Oseltamivir Pharmacology in Young Children: A Commentary.
MedLine Citation:
PMID:  23675921     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Oseltamivir is listed by the World Health Organization as an essential drug for the treatment and prophylaxis of both seasonal and pandemic influenza. Since influenza mortality is highest in neonates and infants, optimal dosing of oseltamivir in this high risk population is of utmost public health concern. To date, only two major clinical trials have been conducted investigating oselatmivir exposure and exposure/response in neonates and infants. The first study was a prospective, open label pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir in a total of 87 young children less than 2 years of age and was conducted by the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG). The second Roche sponsored study was also an open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir in the treatment of 65 children less than 12 months of age. A recent supplemental new drug application (sNDA) was submitted to the Food and Drug Administration (FDA) on the basis of these two studies which resulted in oseltamivir becoming the first and so far only neuraminidase inhibitor to gain FDA approval for treatment of influenza in neonates and infants less than 1 year of age. The two review articles in this volume discuss the complex pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate from different perspectives while attempting to contrast and critique differing literature views of the optimal dose in neonates, infants and young children. The articles also offer suggestions to generate more robust pediatric PKPD data and mend current gaps in knowledge.
Authors:
Mohamed A Kamal
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-5-08
Journal Detail:
Title:  Infectious disorders drug targets     Volume:  -     ISSN:  2212-3989     ISO Abbreviation:  Infect Disord Drug Targets     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-5-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269158     Medline TA:  Infect Disord Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Hoffmann-La Roche, Department of Clinical Pharmacology, 340 Kingsland St., Nutley, NJ 07110-119, mohamed.kamal@roche.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cleavage of Carbon-Carbon Triple Bond: Direct Transformation of Alkynes to Nitriles.
Next Document:  Pharmacokinetics and Pharmacodynamics of Oseltamivir in Neonates, Infants and Children.